S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
The Retirement of Your Dreams Awaits You… (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
The Retirement of Your Dreams Awaits You… (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
The Retirement of Your Dreams Awaits You… (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
The Retirement of Your Dreams Awaits You… (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
NASDAQ:INKT

MiNK Therapeutics (INKT) Stock Price, News & Analysis

$0.90
-0.03 (-3.23%)
(As of 02/23/2024 ET)
Today's Range
$0.89
$0.94
50-Day Range
$0.84
$1.12
52-Week Range
$0.75
$3.34
Volume
35,701 shs
Average Volume
55,644 shs
Market Capitalization
$31.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50

MiNK Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
622.2% Upside
$6.50 Price Target
Short Interest
Healthy
1.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.67) to ($0.65) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.40 out of 5 stars

Medical Sector

734th out of 941 stocks

Biological Products, Except Diagnostic Industry

131st out of 158 stocks


INKT stock logo

About MiNK Therapeutics Stock (NASDAQ:INKT)

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

INKT Stock Price History

INKT Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
MiNK Therapeutics Inc INKT
MiNK Therapeutics GAAP EPS of -$0.15
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
MiNK Therapeutics Reports Third Quarter 2023 Results
MiNK Therapeutics Insider Ups Holding During Year
MiNK Therapeutics Reports Second Quarter 2023 Results
MiNK's Novel FAP-CAR-iNKT Presented at ASGCT
Recap: MiNK Therapeutics Q1 Earnings
See More Headlines
Receive INKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/10/2023
Today
2/23/2024
Next Earnings (Estimated)
3/19/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:INKT
Fax
N/A
Employees
37
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.50
High Stock Price Target
$10.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+606.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-27,990,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.01) per share

Miscellaneous

Free Float
28,372,000
Market Cap
$31.76 million
Optionable
No Data
Beta
0.04
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Garo H. Armen Ph.D. (Age 71)
    Executive Chairman
  • Dr. Jennifer S. Buell Ph.D. (Age 49)
    President, CEO & Director
    Comp: $812.78k
  • Dr. Marcus Antonius van Dijk Ph.D. (Age 62)
    Chief Scientific Officer
    Comp: $369.92k
  • Ms. Christine M. Klaskin (Age 58)
    Treasurer
    Comp: $27.24k
  • Ms. Heather Boussios
    General Counsel & Chief Compliance Officer
  • Joy Zhou Ph.D.
    Vice President & Head of CMC














INKT Stock Analysis - Frequently Asked Questions

Should I buy or sell MiNK Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MiNK Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INKT shares.
View INKT analyst ratings
or view top-rated stocks.

What is MiNK Therapeutics' stock price target for 2024?

3 equities research analysts have issued 12-month target prices for MiNK Therapeutics' stock. Their INKT share price targets range from $3.00 to $10.00. On average, they expect the company's share price to reach $6.50 in the next year. This suggests a possible upside of 622.2% from the stock's current price.
View analysts price targets for INKT
or view top-rated stocks among Wall Street analysts.

How have INKT shares performed in 2024?

MiNK Therapeutics' stock was trading at $1.07 on January 1st, 2024. Since then, INKT shares have decreased by 15.9% and is now trading at $0.90.
View the best growth stocks for 2024 here
.

Are investors shorting MiNK Therapeutics?

MiNK Therapeutics saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 189,400 shares, an increase of 8.3% from the January 15th total of 174,900 shares. Based on an average daily volume of 49,900 shares, the days-to-cover ratio is currently 3.8 days. Currently, 2.0% of the shares of the company are sold short.
View MiNK Therapeutics' Short Interest
.

When is MiNK Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 19th 2024.
View our INKT earnings forecast
.

How were MiNK Therapeutics' earnings last quarter?

MiNK Therapeutics, Inc. (NASDAQ:INKT) released its earnings results on Thursday, August, 10th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.01. During the same quarter in the prior year, the business earned ($0.18) EPS.

When did MiNK Therapeutics IPO?

(INKT) raised $43 million in an initial public offering on Friday, October 15th 2021. The company issued 3,333,334 shares at $12.00-$14.00 per share.

Who are MiNK Therapeutics' major shareholders?

MiNK Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (0.12%). Insiders that own company stock include Agenus Inc, Garo H Armen and Ulf Wiinberg.
View institutional ownership trends
.

How do I buy shares of MiNK Therapeutics?

Shares of INKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INKT) was last updated on 2/24/2024 by MarketBeat.com Staff